SSI 2024 Review: Strategic Refinements, Key Investment Updates, and Performance Insights
SSI's 2024 Tracking Portfolio saw a 1% loss, prompting a refined categorization of investment ideas for 2025. Kronos Bio terminated its Genentech...
315 Views
Exploring Active Portfolio Ideas: Company Sales, Strategic Reviews, Buyouts and More
Lifeway Foods anticipates a sale to Danone, with AGM negotiations expected; SpringWorks Therapeutics in buyout talks with Merck KGaA.
31 Views
Strategic Reviews, Liquidations, and Buybacks: Key Financial Developments in Biopharma, Real Estate
Kronos Bio (KRON) undergoes strategic review with 83% workforce reduction and CEO resignation, trading below net cash value.
31 Views
Kronos Bio Strategic Review: Workforce Reduction, Leadership Changes, and Potential Sale Amid Genentech Partnership Uncertainty
Kronos Bio's NAV is estimated at $1.39/share, 48% above current price, with strategic review ongoing for sale/reverse merger.
349 Views
Strategic Reviews, Mergers, and Asset Sales: Analyzing Upside Potential in Active Portfolio Ideas
Sage Therapeutics rejected Biogen's $7.22/share offer, initiating a strategic review for potential sale, indicating a possible higher premium.
249 Views